Abstract
We describe the feasibility of continuous glucose monitoring (CGM)-enabled insulin-pump therapy during pregnancy in a woman with type 1 diabetes, who was treated with CGM-enabled insulin-pump therapy in her third pregnancy. During her first pregnancy, the woman was treated with multiple daily injections and baseline HbA1c was 8.9%. Due to pre-eclampsia, the child was born preterm, and had neonatal hypoglycemia. In the planning of the second pregnancy, insulin-pump therapy was initiated, resulting in an HbA1c of 6.8% in early pregnancy. Due to pre-eclampsia, the second child was born preterm, but without neonatal morbidity. Before her third pregnancy, CGM-enabled insulin-pump therapy was introduced, and HbA1c was 6.4% in early pregnancy. The patient was satisfied with this therapy, pre-eclampsia did not occur, and the child was born at term without neonatal morbidity. CGM-enabled insulin-pump therapy appears feasible in diabetic pregnancies.
| Original language | English |
|---|---|
| Journal | Acta Obstetricia et Gynecologica Scandinavica |
| Volume | 89 |
| Issue number | 9 |
| Pages (from-to) | 1233-7 |
| Number of pages | 5 |
| ISSN | 0001-6349 |
| DOIs | |
| Publication status | Published - 1 Sept 2010 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS